Health And Pharma
Health & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
About Us - Health And Pharma
Health & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
ONCOLife | Health And Medicine
About ONCOLife. ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is dedicated to covering key developments in the field of oncology.
Posts | Health And Medicine
Dec 21, 2024 · Health & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
FDA Approves Sotorasib and Panitumumab Combination: …
2 days ago · The U.S. FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS G12C-mutated metastatic colorectal cancer (mCRC). This innovative approach, targeting both KRAS and EGFR pathways, significantly improves progression-free survival ...
FDA Approves 225Ac-SSO110 Radiopharmaceutical Trial for Small …
5 days ago · About Ariceum and Satoreotide. Ariceum’s lead targeted systemic radiopharmaceutical candidate, SSO110 (“satoreotide”) labelled with Lutetium-177 (177Lu) and Actinium-255 (255Ac) is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in aggressive neuroendocrine tumours (NETs) such as small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC), all of which ...
FDA Approves Innovative ADC Datroway for Unresectable or …
1 day ago · Dr. Aditya Bardia, a key figure in breast oncology at UCLA Health, emphasized the importance of this achievement: “Despite considerable progress in the HR-positive, HER2-negative metastatic breast cancer treatment landscape, new therapies are still needed to tackle the frequent and complex challenge of disease progression after …
Olaparib Shows Long-term Survival Benefits in BRCA+ and HER2
Dec 13, 2024 · A Transformative Option in Early-Stage Disease. When first announced in 2022, the OlympiA findings led to regulatory approval of olaparib in the adjuvant (post-surgery) setting for certain patients with HER2-negative, BRCA-positive breast cancer.
AbbVie Acquires Nimble in $200 Million Deal to Strengthen …
Dec 13, 2024 · AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for psoriasis, and a robust portfolio of autoimmune disease therapies.
FDA Approves Ziihera as First Dual HER2-Targeted Therapy for …
Nov 22, 2024 · Clinical Trial Insights. The HERIZON-BTC-01 trial assessed the efficacy of Ziihera in 62 patients with HER2-positive BTC, achieving a confirmed objective response rate of 52%. The trial not only met its primary endpoints but also provided hope for improved survival outcomes, with a median duration of response nearing 15 months.